News
10 April 2018
CANTAB Recruit software to be used in two major Phase III drug trials
We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.
Read on
26 March 2018
Cambridge Cognition announces major contract win and funding award
We're pleased to announce the award of a major new pharmaceutical clinical trial contract and a Digital Health Catalyst grant from Innovate UK.
Read on
5 March 2018
Join us at SIRS 2018
Cambridge Cognition are attending the Schizophrenia International Research Society Conference (SIRS): 4th - 8th April 2018
Read on
28 February 2018
WEBINAR: Finding the right patients for clinical trials in early Alzheimer’s disease
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, are hosting a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT
Read on
3 January 2018
WEBINAR: Overcoming methodological challenges to enhance study success in schizophrenia trials
Dr Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr Steve Brannan, Chief Medical Officer, Karuna Pharmaceuticals Inc. hosted a webinar on how to improve clinical trial success in schizophrenia.
Read on
30 November 2017
CANTAB Mobile and CANTAB Insight are now TGA approved for Australian market
We’re delighted to announce that both CANTAB Mobile and CANTAB Insight medical devices, designed for the assessment of cognitive health in clinical practice, have been approved for marketing in Australia by the Therapeutic Goods Administration (TGA) (ARTG No. 294119).
Read on
28 November 2017
Cognition Kit wearable technology demonstrates high compliance among patients with major depressive disorder (MDD)
At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.
